Clinical development of MVA-based therapeutic cancer vaccines.

Abstract:

:Tumor-associated antigens (TAAs) have been formulated into vaccines that, combined with adjuvants, cytokines or other strategies to boost the immune response, are now in clinical development. Both humoral and cellular immune responses to TAAs have been generated using these vaccines. This approach relies on the patient's own immune system generating an effective anti-tumor immune response. The advantage of this over therapy with monoclonal antibodies for the treatment of cancer is that multiple antigenic epitopes can be involved and the immune system is able to adapt to the most effective antigenic specificity for tumor growth control and rejection. In this article, we describe the clinical use of vaccinia virus, in particular modified vaccinia virus Ankara (MVA), to express TAAs in vivo and to stimulate an effective immune response to the cancer antigens.

journal_name

Expert Rev Vaccines

authors

Acres B,Bonnefoy JY

doi

10.1586/14760584.7.7.889

subject

Has Abstract

pub_date

2008-09-01 00:00:00

pages

889-93

issue

7

eissn

1476-0584

issn

1744-8395

journal_volume

7

pub_type

杂志文章,评审
  • Improving vaccines by incorporating immunological coadjuvants.

    abstract::While vaccination continues to be the most successful interventionist health policy to date, infectious disease remains a significant cause of death worldwide. A primary reason that vaccination is not able to generate effective immunity is a lack of appropriate adjuvants capable of initiating the desired immune respon...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.6.4.559

    authors: Fraser CK,Diener KR,Brown MP,Hayball JD

    更新日期:2007-08-01 00:00:00

  • Intracellular detection and immune signaling pathways of DNA vaccines.

    abstract::Parallel to attenuated and subunit vaccines, DNA vaccines require adjuvant signals in addition to antigen presentation for the induction of adaptive immune responses. As opposed to common beliefs, increasing evidence is showing that Toll-like receptor 9 activation by CpG motifs present in DNA vaccines are not vital fo...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.09.79

    authors: Tang CK,Pietersz GA

    更新日期:2009-09-01 00:00:00

  • Cancer vaccines as a therapeutic strategy.

    abstract::The concept of cancer vaccines is as a therapeutic strategy to immunize the body against cancer antigens that may not be presented by the cancer itself, due to the marked immunosuppressive effects of the disease, which has been demonstrated in many different tumors. ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1586/14760584.3.6.665

    authors: Dalgleish AG

    更新日期:2004-12-01 00:00:00

  • In utero exposure to biologic disease-modifying anti-rheumatic drugs and effects to the infant: infectious complications, vaccine response, and safety of live vaccine administration.

    abstract:INTRODUCTION:Biologic disease-modifying anti-rheumatic drugs (bDMARDS) are increasingly used in clinical practice for a variety of conditions. Due to concerns surrounding persistence of drug levels and resulting immunosuppression, current case reports recommend against live vaccine administration in the first year of l...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2019.1599286

    authors: Berkhout A,Clark JE,Wen SC

    更新日期:2019-05-01 00:00:00

  • Optimizing vaccine-induced CD8(+) T-cell immunity: focus on recombinant adenovirus vectors.

    abstract::Recombinant adenoviruses have emerged as promising viral vectors for CD8(+) T-cell vaccines. Our studies have indicated that unlike most acute infections, the CD8(+) T-cell memory population elicited by recombinant human adenovirus serotype 5 (rHuAd5) displays a dominant effector memory phenotype. Persistent, low-leve...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.88

    authors: Bassett JD,Swift SL,Bramson JL

    更新日期:2011-09-01 00:00:00

  • Molecular mechanisms for enhanced DNA vaccine immunogenicity.

    abstract::In the two decades since their initial discovery, DNA vaccines technologies have come a long way. Unfortunately, when applied to human subjects inadequate immunogenicity is still the biggest challenge for practical DNA vaccine use. Many different strategies have been tested in preclinical models to address this proble...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2016.1124762

    authors: Li L,Petrovsky N

    更新日期:2016-01-01 00:00:00

  • Vaccines in leishmaniasis: advances in the last five years.

    abstract::The leishmaniases are a group of diseases caused by protozoa of the genus Leishmania which affects millions of people worldwide. The leishmaniases are transmitted to the vertebrate hosts by phlebotomine sand flies. In this review, we focus on clinical aspects of the leishmaniases and on the immune response against the...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2.5.705

    authors: Brodskyn C,de Oliveira CI,Barral A,Barral-Netto M

    更新日期:2003-10-01 00:00:00

  • SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier.

    abstract::The authors have purified a major capsid protein, VP1 of Simian virus 40 (SV40), using recombinant baculovirus and have established the method of in vitro reassembly of SV40 virus-like particles (SV40-VLPs) from VP1-pentamers. In this reassembly, SV40-VLPs can encapsulate approximately 5 kb exogenous DNA shielded by h...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.12.149

    authors: Kawano M,Matsui M,Handa H

    更新日期:2013-02-01 00:00:00

  • Recombinant cancer vaccines and new vaccine targets. Interview by Jenaid Rees.

    abstract::Interview by Jenaid Rees, Commissioning Editor Jeffrey Schlom obtained his PhD from Rutgers University (NJ, USA). After obtaining his PhD, he worked at Columbia University (NY, USA) before moving in 1973 to the National Cancer Institute, National Institutes of Health (MD, USA). Since then he has served as the Chief of...

    journal_title:Expert review of vaccines

    pub_type: 传,历史文章,面试

    doi:10.1586/14760584.2013.836913

    authors: Schlom J

    更新日期:2013-10-01 00:00:00

  • Prospects for vaccine development against Buruli disease.

    abstract::Buruli disease, caused by Mycobacterium ulcerans, is an emerging infectious disease in tropical areas, particularly West Africa, which can cause deep necrotizing skin lesions, called Buruli ulcer. Buruli disease affects all age groups but about 50% of the cases are diagnosed in children. There is no evidence that Buru...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2.4.561

    authors: Huygen K

    更新日期:2003-08-01 00:00:00

  • Breast cancer vaccines: current research and future prospects.

    abstract::Although the immune system can clearly recognize cancer cells, there is little evidence that it does so to any effective consequence in patients with advanced breast cancer. The possibility of effective control of micrometastatic disease remains but is unproven. The challenge for the clinician is to find ways to enhan...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.1.1.29

    authors: Cameron DA

    更新日期:2002-06-01 00:00:00

  • A call for replicating vector prime-protein boost strategies in HIV vaccine design.

    abstract::A key challenge to HIV vaccine development is the integration of HIV proviral DNA into the host genome upon infection. Therefore, an optimal vaccine should block infection within hours of viral exposure, providing 'sterilizing immunity' at mucosal sites and in blood via potent, broadly reactive antibody to the HIV env...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.3.4.s105

    authors: Malkevitch NV,Robert-Guroff M

    更新日期:2004-08-01 00:00:00

  • The potential of plants for the production and delivery of human papillomavirus vaccines.

    abstract::The available vaccines against human papillomavirus have some limitations such as low coverage due to their high cost, reduced immune coverage and the lack of therapeutic effects. Recombinant vaccines produced in plants (genetically engineered using stable or transient expression systems) offer the possibility to obta...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.1037744

    authors: Rosales-Mendoza S,Govea-Alonso DO

    更新日期:2015-07-01 00:00:00

  • Challenges of Global Vaccine Development.

    abstract::The Keystone Symposia conference, Challenges of Global Vaccine Development, attracted approximately 440 scientists, physicians and students from all around the world. The conference goal was to share newly acquired knowledge regarding vaccine-induced immunity, novel technologies, childhood vaccines, preclinical models...

    journal_title:Expert review of vaccines

    pub_type:

    doi:10.1586/14760584.7.1.21

    authors: Gudmundsdotter L,Hallengärd D

    更新日期:2008-02-01 00:00:00

  • Specific Lactobacillus species differentially activate Toll-like receptors and downstream signals in dendritic cells.

    abstract:BACKGROUND:Dendritic cells (DCs) regulate mucosal T-cell immunity and encounter several distinct bacteria of the gut flora, including lactobacilli. Gram-positive lactobacilli have been suggested to play an important role in exerting adjuvanticity effects on innate immune cells at mucosal sites. AIMS & METHODS:In the p...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1586/14760584.7.8.1155

    authors: Mohamadzadeh M,Klaenhammer TR

    更新日期:2008-10-01 00:00:00

  • Challenges in estimating influenza vaccine effectiveness.

    abstract::Introduction: Influenza vaccination is regarded as the most effective way to prevent influenza infection. Due to the rapid genetic changes that influenza viruses undergo, seasonal influenza vaccines must be reformulated and re-administered annually necessitating the evaluation of influenza vaccine effectiveness (VE) e...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2019.1622419

    authors: Ainslie KEC,Haber M,Orenstein WA

    更新日期:2019-06-01 00:00:00

  • Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations.

    abstract::Introduction Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), has quickly spread around the world. Areas covered This review will discuss the available immunologic and clinical evidence to support the benefit of the influenza, pneumococcal, and tuberculosis vaccines...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2020.1825951

    authors: Sultana J,Mazzaglia G,Luxi N,Cancellieri A,Capuano A,Ferrajolo C,de Waure C,Ferlazzo G,Trifirò G

    更新日期:2020-10-01 00:00:00

  • Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development.

    abstract::Several subtypes of influenza A viruses with pandemic potential are endemic in bird populations throughout Asia, Africa and the Middle East, and evidence suggests that these viruses are adapting to the mammalian host. As emphasized by the high mortality rate of humans infected with H5N1 viruses, this situation present...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.13.21

    authors: Barrett PN,Portsmouth D,Ehrlich HJ

    更新日期:2013-04-01 00:00:00

  • Suppressor of cytokine signaling 1 inhibition strategy to enhance anti-HIV vaccination.

    abstract::Extensive efforts aimed at stimulating immune responses by modifying HIV antigens and using various delivery systems and adjuvants have so far failed to generate promising HIV vaccines, highlighting the urgent need to explore alternative immunization approaches. Antigen-presenting cells, such as dendritic cells, play ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.5.4.495

    authors: Song XT,Aldrich M,Chen SY

    更新日期:2006-08-01 00:00:00

  • Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.

    abstract::Although mass vaccination of the entire population of an endemic area would be the most cost-effective tool to diminish Leishmania burden, an effective vaccine is not yet commercially available. Practically, vaccines have failed to achieve the required level of protection, possibly owing to the lack of an appropriate ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.166

    authors: Doroud D,Rafati S

    更新日期:2012-01-01 00:00:00

  • Vaccines for lyssaviruses other than rabies.

    abstract::Several new lyssaviruses have emerged in the past decade and it is likely that more remain to be discovered. There are six recognized genotypes of lyssavirus other than the rabies virus (genotype 1). All but one of these has been associated with human cases, with the resulting disease clinically similar to rabies. Rab...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.4.4.533

    authors: Nel LH

    更新日期:2005-08-01 00:00:00

  • DNA-launched live-attenuated vaccines for biodefense applications.

    abstract::A novel vaccine platform uses DNA immunization to launch live-attenuated virus vaccines in vivo. This technology has been applied for vaccine development against positive-strand RNA viruses with global public health impact including alphaviruses and flaviviruses. The DNA-launched vaccine represents the recombinant pla...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2016.1175943

    authors: Pushko P,Lukashevich IS,Weaver SC,Tretyakova I

    更新日期:2016-09-01 00:00:00

  • CpG DNA as a vaccine adjuvant.

    abstract::Synthetic oligodeoxynucleotides containing unmethylated CpG motifs act as immune adjuvants, accelerating and boosting antigen-specific antibody responses by up to 500-fold. CpG motifs promote the production of T-helper 1 and pro-inflammatory cytokines and induce the maturation/activation of professional antigen-presen...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2.2.305

    authors: Klinman DM

    更新日期:2003-04-01 00:00:00

  • Peptidomimetics: modifying peptides in the pursuit of better vaccines.

    abstract::Peptide vaccines represent a potential strategy for the prevention and treatment of pathogenic diseases, cancers and autoimmune disorders; their low cost, ease of synthesis and inherent safety are all attractive features. However, they have remained largely unsuccessful owing to low immunogenicity, predominantly stemm...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.10.161

    authors: Croft NP,Purcell AW

    更新日期:2011-02-01 00:00:00

  • Prospects for antibody-based universal influenza vaccines in the context of widespread pre-existing immunity.

    abstract::Influenza inflicts significant global mortality and morbidity that can be combated by effective immunization. However, the protective efficacy of current vaccines is limited by both the significant antigenic diversity of the viral hemagglutinin protein and the capacity for rapid antigenic change. This necessitates glo...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.1068125

    authors: Wheatley AK,Kent SJ

    更新日期:2015-01-01 00:00:00

  • Immunological assessment of influenza vaccines and immune correlates of protection.

    abstract::Influenza vaccines remain the primary public health tool in reducing the ever-present burden of influenza and its complications. In seeking more immunogenic, more effective and more broadly cross-protective influenza vaccines, the landscape of influenza vaccines is rapidly expanding, both in near-term advances and nex...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.13.35

    authors: Reber A,Katz J

    更新日期:2013-05-01 00:00:00

  • The Ebola virus glycoprotein and its immune responses across multiple vaccine platforms.

    abstract::Introduction: For over 40 years, ebolaviruses have been responsible for sporadic outbreaks of severe and often fatal hemorrhagic fever in humans and nonhuman primates across western and central Africa. In December 2013, an unprecedented Ebola virus (EBOV) epidemic began in West Africa and resulted in the largest outbr...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2020.1738225

    authors: O'Donnell K,Marzi A

    更新日期:2020-03-01 00:00:00

  • Solid vaccine protection against SIV in rhesus monkeys provides proof-of-concept for further evaluation of a novel HIV vaccine approach in humans.

    abstract::Protection against acquisition of fully heterologous, neutralization-resistant SIV was achieved in rhesus monkeys with adenovirus/poxvirus vector-based vaccines. Protection against acquisition of infection required the inclusion of envelope antigens and correlated with the induction of binding antibodies against the E...

    journal_title:Expert review of vaccines

    pub_type: 评论,杂志文章

    doi:10.1586/erv.12.21

    authors: Esparza J

    更新日期:2012-05-01 00:00:00

  • Plant production systems for vaccines.

    abstract::Plants offer an attractive alternative for the production and delivery of subunit vaccines. Various antigens have been expressed at sufficiently high levels in plants to render vaccine development practical. An increasing body of evidence demonstrates that these plant-produced antigens can induce immunogenic responses...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2.6.763

    authors: Streatfield SJ,Howard JA

    更新日期:2003-12-01 00:00:00

  • Clinical experience with the inactivated hepatitis A vaccine, Avaxim 80U Pediatric.

    abstract:INTRODUCTION:Hepatitis A, caused by hepatitis A virus (HAV), is primarily transmitted via the fecal/oral route either through ingestion of contaminated food and water or through direct contact with an infectious person. Prevalence of hepatitis A is strongly correlated with socioeconomic factors, decreasing with increas...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2019.1580578

    authors: Bravo C,Mege L,Vigne C,Thollot Y

    更新日期:2019-03-01 00:00:00